Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematologic Malignancies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Hematologic Malignancies. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2018-002793-47 Sponsor Protocol Number: MKIA-088-001 Start Date*: 2019-01-16
    Sponsor Name:NERVIANO MEDICAL SCIENCES SRL
    Full Title: A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
    Medical condition: Acute myeloidleukemia (AML) or chronic myelomonocytic leukemia (CMML) relapsed or refractory.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054296 Acute myeloid leukemia NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000534-35 Sponsor Protocol Number: CSM/CIT Start Date*: 2013-07-12
    Sponsor Name:Fundación Castellano Leonesa de Hematología y Hemoterapia (FUCALHH)
    Full Title: Phase II clinical trial in the treatment of cytopenias allogeneic post-transplant with a sequential infusion of allogeneic mesenchymal cells expanded in vitro.
    Medical condition: Allogeneic post-transplant cytopenias.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001445-61 Sponsor Protocol Number: FLO-02 Start Date*: 2016-09-12
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Open label, multi-centre, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety of febuxostat between pediatric patients (≥6<18 years of age) and adults.
    Medical condition: Hematological malignancies at intermediate to high risk of Tumor Lysis Syndrome ( TLS) prevention.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10045170 Tumour lysis syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018594-37 Sponsor Protocol Number: EMN-alloRIC2010 Start Date*: 2013-01-24
    Sponsor Name:European Myeloma Network
    Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients
    Medical condition: Allogeneic transplantation for patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022978-14 Sponsor Protocol Number: A8081013 Start Date*: 2011-02-10
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
    Medical condition: Treatment of tumors with translocation, mutation, or amplification of the anaplastic lymphoma kinase (ALK)gene locus.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000744-55 Sponsor Protocol Number: M15-954 Start Date*: 2020-10-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Hig...
    Medical condition: Myelodysplastic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004318-16 Sponsor Protocol Number: DAS181-3-01 Start Date*: 2020-01-16
    Sponsor Name:Ansun Biopharma, Inc.
    Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033796 Parainfluenzae viral infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003573-28 Sponsor Protocol Number: V87_26 Start Date*: 2014-02-06
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase III Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elde...
    Medical condition: Pandemic Influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004535-12 Sponsor Protocol Number: KO-TIP-001 Start Date*: 2016-02-25
    Sponsor Name:Kura Oncology, Inc.
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
    Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    18.1 10018065 - General disorders and administration site conditions 10071971 H-ras gene mutation PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004246-20 Sponsor Protocol Number: 20810 Start Date*: 2018-03-06
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-1...
    Medical condition: NTRK fusion cancers previously treated with a TRK inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049516 Malignant tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IE (Completed) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016378-34 Sponsor Protocol Number: MI-CP204 Start Date*: 2010-06-30
    Sponsor Name:MedImmune LLC
    Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
    Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004076-34 Sponsor Protocol Number: 7487-CL-0209 Start Date*: 2014-02-27
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017147-33 Sponsor Protocol Number: AGMT_CMML1 Start Date*: 2010-02-10
    Sponsor Name:AGMT gemeinnützige GmbH
    Full Title: A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia
    Medical condition: Chronic Myelomonocytic Leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10054350 Chronic myelomonocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001735-10 Sponsor Protocol Number: 21816 Start Date*: 2021-05-28
    Sponsor Name:Bayer AG
    Full Title: COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in parti...
    Medical condition: Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004883-23 Sponsor Protocol Number: APHP191116 Start Date*: 2020-10-06
    Sponsor Name:APHP
    Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adu...
    Medical condition: Adult patients (n=10) requiring an allogeneic HSCT for the treatment of AML with an unfavorable prognosis according to international criteria in first complete remission or second complete remissio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005013-14 Sponsor Protocol Number: MKIA-088-002 Start Date*: 2022-01-11
    Sponsor Name:NERVIANO MEDICAL SCIENCES SRL
    Full Title: A Phase I/II Combination Study of NMS-03592088 And Azacitidine for the Treatment of Patients With FLT3-Mutated AML with Relapsed /Refractory Disease or Who Are Unfit For Intensive Chemotherapy, or ...
    Medical condition: Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028552 Myeloid leukaemia, acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001465-24 Sponsor Protocol Number: GC-LTFU-001 Start Date*: 2018-02-26
    Sponsor Name:Celgene Corporation
    Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
    Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025631 Malignant lymphoid neoplasm NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005843-21 Sponsor Protocol Number: KT-US-982-5968 Start Date*: 2022-02-08
    Sponsor Name:KITE PHARMA INC.
    Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells
    Medical condition: B-cell malignancies and Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081514 Acute myeloid leukemia refractory LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006599 Burkitt's lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004572-30 Sponsor Protocol Number: GS-US-406-1840 Start Date*: 2016-03-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as Fi...
    Medical condition: Chronic Graft Versus Host Disease (cGVHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 02 21:16:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA